

A Systematic Review of the State of Economic Evaluation for Health Care in India

Shankar Prinja¹ · Akashdeep Singh Chauhan¹ · Blake Angell² · Indrani Gupta³ · Stephen Jan^{2,4}

© Springer International Publishing Switzerland 2015

Abstract

Background and objective Economic evaluations are one of the important tools in policy making for rational allocation of resources. Given the very low public investment in the health sector in India, it is critical that resources are used wisely on interventions proven to yield best results. Hence, we undertook this study to assess the extent and quality of evidence for economic evaluation of health-care interventions and programmes in India.

Methods A comprehensive search was conducted to search for published full economic evaluations pertaining to India and addressing a health-related intervention or programme. PubMed, Scopus, Embase, ScienceDirect, and York CRD database and websites of important research agencies were identified to search for economic evaluations published from January 1980 to the middle of November 2014. Two researchers independently assessed the quality of the studies based on Drummond and modelling checklist.

Results Out of a total of 5013 articles enlisted after literature search, a total of 104 met the inclusion criteria for this systematic review. The majority of these papers were cost-effectiveness studies (64 %), led by a clinician or public-health professional (77 %), using decision analysis-based methods (59 %), published in an international journal (80 %) and addressing communicable diseases (58 %). In addition, 42 % were funded by an international funding agency or UN/bilateral aid agency, and 30 % focussed on pharmaceuticals. The average quality score of these full economic evaluations was 65.1 %. The major limitation was the inability to address uncertainties involved in modelling as only about one-third of the studies assessed modelling structural uncertainties (33 %), or ran sub-group analyses to account for heterogeneity (36.5 %) or analysed methodological uncertainty (32 %).

Conclusion The existing literature on economic evaluations in India is inadequate to feed into sound policy making. There is an urgent need to generate awareness within the government of how economic evaluation can inform and benefit policy making, and at the same time build capacity of health-care professionals in understanding the economic principles of health-care delivery system.

Electronic supplementary material The online version of this article (doi:10.1007/s40258-015-0201-6) contains supplementary material, which is available to authorized users.

✉ Shankar Prinja
shankarprinja@gmail.com

¹ School of Public Health, Post Graduate Institute of Medical Education and Research, Sector-12, Chandigarh 160012, India

² The George Institute for Global Health, Camperdown, NSW 2050, Australia

³ Health Policy Research Unit, Institute of Economic Growth, University of Delhi Enclave, Delhi 110007, India

⁴ Sydney Medical School, University of Sydney, Sydney, Australia

Key Points for Decision Makers

There is a relative dearth of economic evaluation evidence for health-care interventions in India.

The quality of economic evaluation studies for health care in India needs improvement, especially in addressing the uncertainties involved in the modelling estimates.

There is a need to generate capacity of researchers to undertake quality economic evaluations, as well as an orientation of the policy makers so that there is demand for such studies as well as a scope for its use in policy making.

1 Introduction

In high income countries (HIC) such as USA, UK, Canada and Western European countries, policies to promote the use of evidence on value for money have long been in place [1–3]. Countries in the South East Asia region (SEAR) such as Taiwan, Malaysia and Thailand have also institutionalised health-technology assessment processes (HTA) into certain areas of policy. These policy measures have strengthened the imperative in each setting on achieving efficacy, cost effectiveness and value for money in the health sector [4, 5].

Recent initiatives in India have indicated a growing recognition of the important role of economic evidence in setting health-sector priorities. For instance, the National Technical Advisory Group on Immunization (NTAGI) was set up to inform decision making for introduction of new vaccines and strengthening the Universal Immunisation Programme (UIP) [6]. The Department of Health Research in India has recently set up a Medical Technology Assessment Board (MTAB) for evaluation of appropriateness and cost effectiveness of the available and new health technologies in India [7]. The MTAB aims to encourage investment in cost-effective interventions that will reduce the cost and variations in patient care, expenditure on medical equipment in directly affecting the cost of patient care, overall cost of medical treatment, reduction in out-of-pocket expenditure of patients and streamline the medical reimbursement procedures. Also, recently, the Indian chapter of International Society for Pharmacoeconomics and Outcomes Research (ISPOR) produced guidelines on how to conduct high-quality economic evaluation studies [8]. ISPOR provides an environment for knowledge sharing

among researchers, health-care practitioners and decision makers interested in pharmacoeconomics and outcomes research.

A recent systematic review of pharmacoeconomic studies from India found 29 articles published during the period from 1998 to 2012 [9]. However, this review covered only economic evaluation studies which focussed on drugs. Moreover, the review included both full economic evaluations (cost per outcome description with comparison of alternatives) as well as simple cost analyses. Another systematic review from India by Mishra et al. found 132 articles published between 1999 and 2012 [10]. However, this was not focussed on full economic evaluations alone, and included several other studies such as cost-only analysis and studies which measured changes in outcome (estimation of quality of life) alone. Following both these reviews the present review breaks new ground in assessing full economic evaluations on all health-care interventions and programmes reported from India.

Given the very low public investment in the health sector, it is critical that resources are used wisely on those interventions that are proven to yield best results. Sound investment decisions require technical evaluations, and it is important at this juncture of policy environment to assess progress that has been made in generating a body of evidence around cost effectiveness of health programmes in India. Hence we undertook this study to assess the extent and quality of evidence for economic evaluation of health-care interventions or programmes in India. Based on the results, we indicate how India might move ahead to optimise resource use in its various health programmes and interventions. While it may be possible that some evaluation results have gone directly into government policies without being published, we believe it is not very probable given that sound evaluation studies are highly publishable.

2 Methods

2.1 Search Strategy

A comprehensive computerised search was conducted in November 2014 to search for published health economic evaluations pertaining to India and addressing a health-related intervention or programme. PubMed, Scopus, Embase, ScienceDirect and York CRD (Centre for Reviews and Dissemination) database were identified to search for evaluations published from January 1980 to the middle of November 2014. Website search of some important UN agencies (World Health Organization, World Bank and Asian Development Bank) and an Indian economic research agency (National Council of Applied Economic Research) was also carried out. The search




Fig. 1 Flow diagram showing study selection

strategy and the keywords are presented in “Box 1” and Figure 1. The key words were checked for controlled vocabulary under Medical Subject Headings (MeSH) of PubMed, and ‘exploded’ in the database thesauri.

Library staff of Post-Graduate Institute of Medical Education and Research (PGIMER), and the research staff from the Advanced Centre for Evidence-Based Child Health in the department of Paediatrics, Post-Graduate Institute of Medical Education and Research, Chandigarh were consulted to finalise the search strategy. The review included only peer-reviewed articles that were reported in the English language and excluded abstracts, reports, expert opinion, narrative reviews, etc. To our knowledge, all of the seven leading Indian journals on economics and health economics that are published in local languages are also published in English language. Hence, we did not include papers published in non-English language.

2.2 Study Selection and Inclusion Criteria

The studies were selected based on a two-stage screening process as shown in Fig. 1. The search started by screening

the titles and abstracts of all articles found in the initial search from the databases and websites. Based on the screening of titles and abstracts for removing duplicates, potentially relevant studies were selected for further review, which involved examining the content of their full text. In the second-stage screening, only those studies were considered, which were full health economic evaluations, i.e. comparing both costs and outcomes of two or more interventions and excluding partial economic evaluations and cost-only analysis. Only those peer-reviewed papers which presented a full economic evaluation of a health-care intervention or programme pertaining to India, published in English during 1980 to November 2014 were considered eligible for full review. At this stage, a bibliographic search of the selected studies was carried out to identify additional relevant economic evaluations. The search was continued until no new article was found. Two authors (ASC and BA) had access to abstract and full text of the paper to decide on its inclusion. Discrepancies between the two investigators were solved by discussion with the lead author (SP). Efforts were made to remove any bias by following strict criteria for inclusion of studies in the review. Three authors

for the present review are health economists, with two authors having significant experience of undertaking systematic reviews. Two of the authors have additional background as medical professionals.

2.3 Data Extraction and Quality Appraisal

A standardised data extraction form was developed to collect the general and methodological data from the selected studies. An electronic data collection form was used, which was designed by the same people who extracted the data. Section 7.5.3 of Cochrane Review Handbook was consulted while designing of this form [11]. For assessing the quality of studies, Drummond checklist developed by Drummond et al. was used [12]. For evaluating studies based on a decision model, decision-analytic modelling checklist was adapted from guidelines developed by Philips et al. [13]. A weighted version of Drummond checklist developed by La Torre et al. was used to give a composite score to each study based on its quality [14].

The general information section of the data extraction form included the following items: year of publication, lead and corresponding author, institutional affiliation, number of authors, country of residence of lead author, profession of the lead author, publishing journal, country of the journal (Indian or foreign), funding source, disease/subject area of the study and the type of intervention (pharmaceuticals, public-health programme, service delivery, etc.). The methodological section included the following: type of economic evaluation, study design, perspective, time period, discount rate, the primary outcomes, type of costs and sensitivity analysis. Drummond checklist, which assessed the quality, comprised 35 items divided into three sections: study design, data collection and analysis and interpretation of results. For each quality item, a response was recorded either as ‘yes,’ ‘no,’ ‘not clear’ or ‘not applicable.’ A weighted version of the Drummond checklist was used to compute a composite quality score (global score) for each study based on the weights assigned to each of the 35 items in the checklist. The maximum overall quality score was 119. Weighted scores of individual studies were converted into a percentage. Modelling checklist included 17 items for assessing the model characteristics, model assumptions, quality of secondary data and measures to address uncertainties.

Two researchers (ASC and BA) independently assessed the quality of the studies based on Drummond and modelling checklist. Discrepancies between the two investigators were solved by discussion with the lead author (SP). Kappa statistic was calculated to measure the agreement between the two reviewers.

2.4 Data Analysis

Descriptive statistical analysis, including frequency and percentages, was used to describe the characteristics of the studies. The studies published pre 2005 (including 2005) and post 2005 were compared based on certain general characteristics and quality attributes, using chi square and one-way ANOVA. The year 2005 was used as a cut-off for multiple reasons. Firstly, India’s flagship programme, National Rural Health Mission (NRHM), which led to beginning of decentralised planning process was introduced in 2005. Secondly, India produced its 2nd and more comprehensive National Health Accounts in 2005. At the global level, an impetus to the use of economic evidence for policy planning was provided by release of the report of 2nd edition of the Disease Control Priorities Project in April 2006 [15]. Finally, the planning for a number of publicly financed health insurance schemes in India also started around that period. The association between quality and various factors such as year of publication, lead author affiliation and speciality, focus and type of evaluation, study design, perspective, etc., was also examined. Mendeley software was used to manage the references. Microsoft excel was used for data entry.

Incremental cost effectiveness ratios (ICERs) of all those studies where the primary outcome was reported as disability-adjusted life-years (DALY) or quality-adjusted life-years (QALY) were compared to present a summary evidence for use in India’s policy making. ICERs of all these cost-utility studies were adjusted to 2013 values, based on the wholesale price inflation (WPI) index in India [16]. ICERs of all cost-utility studies, which were reported in US Dollar (US\$) were adjusted for inflation and converted to their values in 2013. Studies which reported ICERs in Indian National Rupee (INR) were first converted to US\$ using currency exchange rates in the year of research and subsequently were adjusted for inflation as done for other cost-utility studies. The WHO Guide to Cost-Effectiveness Analysis (WHO CHOICE) categorises interventions as “highly cost effective” when the ICER is less than the gross domestic product (GDP) per capita, “cost-effective” when the ICER is between one and three times GDP per capita, and “not cost-effective” when the ICER is more than three times higher than GDP per capita [17]. Following these guidelines, the inflation-adjusted ICERs of various interventions, were compared with GDP per capita of India in 2013, which was US\$1500 [18].

3 Results

A total of 5494 articles were identified from databases (4509 from PubMed, 372 from York CRD database, 296 from Embase, 250 from Scopus, 56 from ScienceDirect),

websites ($n = 6$) and bibliographic search ($n = 3$) as shown in Figure 1. After removing duplicates, the remaining 5013 articles were screened by applying inclusion criteria to the titles and abstracts. A total of 4856 articles were excluded in the first-stage screening and 157 studies were identified as eligible for 2nd screening. Full text papers of these 157 studies were reviewed in the second stage. Ultimately, 104 articles were found eligible for this systematic review [19–122].

3.1 General Characteristics of Included Studies

Of the selected studies, the majority (64 %) were cost-effectiveness analyses followed by cost-utility (30 %) and cost-benefit analyses (6 %) as reported in Table 1. Only 20 % studies were published in Indian journals while the remaining (80 %) were published in international journals. The lead author was affiliated to an Indian institution in 39 % of these studies. Among 70 % of studies, either the lead author or a co-author was affiliated to a foreign institution. In most of these economic evaluations, lead authors were clinicians (36 %) or a public-health professional (41 %) with health economists authoring in only 7 % studies. An average number of 6.22 researchers authored the studies. About half of the studies used a provider or payer perspective (48 %) followed by societal perspective in 38 % of the studies. The perspective of study was not clear in 11 % of studies while for about 39 % of studies, perspective of the study was not explicitly stated.

The most common study comparator scenario used in these evaluations was the routine programme or care (41 %) followed by a ‘do-nothing’ scenario for comparison in 37 % of the studies. Decision modelling was used in 63 (61 %) studies, with remaining 41 being the trial based evaluations (39 %). Among trial-based studies, randomised controlled design was reported in 54 % of the studies. Similarly, among model-based studies, Markov model was used in around 50 % of the studies. Secondary data on cost and effectiveness were used in the 46 % and 56 % of the studies, respectively. Utility based outcome measures were used in 29 % (DALY) and 9 % (QALY) of the studies. Remaining studies used clinical end points (20 %), life-years saved (14 %) and illness prevented (20 %) as measures to value consequences or benefits. Around 22.2 % ($n = 14$) of the model-based studies relied on the expert opinion on some of their parameters. Specifically, five studies had used expert opinion to come up with cost estimates, three studies for quality-of-life weight assessment and eight studies for deciding on transitional probabilities/model structure.

Sensitivity analysis was performed in 69 % of the studies, with univariate and multiway analysis being followed in 91.6 % of these studies. Around 16.3 % ($n = 17$)

of the studies had done probabilistic sensitivity analysis, while 3.8 % ($n = 4$) of the studies reported having undertaken bootstrapping to estimate confidence interval for the ICER estimate. Discount rate was stated in 60 % of the studies, with about half (49 %) the studies using a 3 % rate to discount future costs and benefits. In terms of funding, 42 % of the studies were funded either by an international donor or UN/bilateral aid agency. Nearly 34 % studies did not list the funding source, while it was reported as nil in 8 % of the evaluations. Only 6 % economic evaluations in health were commissioned and funded by Indian national or state government. Cost was reported in USD in 67 % of the studies followed by INR in 29 % of the studies.

Around 30 % of these evaluations focussed on pharmaceuticals, 26 % on public-health programme, 19 % on vaccines and 12 % on screening programmes. The interventions that were evaluated, addressed communicable diseases in 58 % of cases, while the remaining focussed on a non-communicable disease or injury. The interventions were mostly (60.5 %) preventive in nature. In a majority of cases the intervention took place in a primary-care setting (60 %), followed by tertiary (27 %) and secondary care (13 %). Around 50 % of the interventions addressed in the evaluations were community based followed by facility-based intervention (45 %). State-wise distribution shows that around 14 % of the interventions were done in Southern India, followed by 7 % in Delhi, 6 % in Gujarat, 5 % in Maharashtra, 3 % each from Andhra Pradesh and Bihar, and 2 % from north eastern state of Sikkim. Around 52 % of the interventions were reported considering India as a whole instead of focussing on any state.

More than three-quarters (78 %) of these evaluations identified limitations of their analysis, while in 69 % studies the authors discussed their findings in light of what others had reported. However, only 36 % of studies had considered the fiscal implications of the intervention on budget, and only 40 % considered generalisability of their findings.

3.2 Characteristics of Studies Before and After 2005

A total of 25 studies were identified as published pre 2005 while 79 were published after 2005 (Fig. 2). The percentage of lead authors from an Indian institution has fallen from 60 % in pre 2005 to 33 % post 2005, which was statistically significant ($p < 0.05$). Other factors which registered a statistically significant increase include: clinician and public-health expert as the lead author, publication in an international journal, HIV/AIDS and tuberculosis as the disease investigated, application of multiway sensitivity analysis and use of 3 % as the discount rate. For some other characteristics such as DALY as the outcome

Table 1 General and methodological characteristics of economic evaluation studies for health-care interventions and programmes in India

Variable	Category	Frequency ^a
Institution affiliation of lead author	From India	41 (39)
Involvement of foreign author		73 (70)
Publishing journal	National	21 (20)
	International	83 (80)
Article nationally or internationally focused	National	87 (84)
	International	17 (16)
Lead author affiliation	Clinician	38 (36)
	Economist	7 (7)
	Public health/research	42 (41)
	Member of UN agency	10 (9)
	Others	7 (7)
Average number of authors (standard deviation)		6.22 (5.73)
Study perspective	Patient	3 (3)
	Provider/payer	50 (48)
	Societal	40 (38)
	Not clear	11 (11)
Study alternative	Do nothing	38 (37)
	Routine care/programme	43 (41)
	Best available Alternative ^b	3 (3)
	Other scenarios	20 (19)
Type of economic evaluation	Cost-effectiveness analysis	67 (64)
	Cost-benefit analysis	6 (6)
	Cost-utility analysis	31 (30)
Study design	Trial based	41 (39)
	Modelling	61 (59)
	Both	2 (2)
Type of trial	Randomised controlled trial	22 (21)
	Non-randomised trial	4 (4)
	Observational study	15 (14)
	Not applicable	63 (61)
Type of model	Markov model	31 (30)
	Decision tree	15 (14.5)
	Not clear	17 (16.5)
	Not applicable	41 (39)
Type of cost data used	Primary	47 (45)
	Secondary	48 (46)
	Both	9 (9)
Type of effectiveness data used	Primary	42 (40)
	Secondary	58 (56)
	Both	4 (4)

Table 1 continued

Variable	Category	Frequency ^a
Time horizon	Less than a year	18 (17)
	1–5 years	22 (21)
	5–10 years	14 (13.5)
	>10 years but not lifetime	13 (13)
	Lifetime	18 (17)
	Not mentioned	19 (18)
Outcome measure	DALY	30 (29)
	QALY	9 (9)
	Clinical end points	21 (20)
	Life years saved	15 (14)
	Deaths averted	6 (6)
	Illness prevented	21 (20)
	Not clear	2 (2)
Type of sensitivity analysis performed	Univariate	36 (34)
	Bivariate	6 (6)
	Multiway	30 (29)
	NA	32 (31)
Discount rate used	3 %	50 (49)
	3.50 %	1 (1)
	5 %	4 (4)
	10 %	7 (7)
	NA	42 (40)
Currency	Indian rupees	30 (29)
	USD	70 (67)
	International dollars	4 (4)
Funding agency	State/national government	6 (6)
	UN/bilateral aid agency	13 (12)
	International donors	31 (30)
	Private agency	3 (3)
	Not mentioned	35 (34)
	Nil	9 (8)
	Multiple funding agencies	7 (7)
Classification by disease type	Communicable diseases	60 (58)
	Non communicable diseases	36 (34)
	Others	8 (8)
Type of intervention	Diagnostic	5 (5)
	Pharmaceuticals	31 (30)
	Vaccine	20 (19)
	Medical device	4 (4)
	Service delivery	4 (4)
	Public-health programme	27 (26)
	Screening	13 (12)

Table 1 continued

Variable	Category	Frequency ^a
Classification of intervention	Community-based intervention	52 (50)
	Facility-based intervention	47 (45)
	Both	5 (5)
Level of care of provision	Primary	62 (60)
	Secondary	14 (13)
	Tertiary	28 (27)
Nature of care	Preventive	63 (60.5)
	Curative	37 (35.5)
	Both	4 (4)
Area wise classification of intervention	Urban	27 (26)
	Rural	9 (9)
	Both	68 (65)
Considered the impact on budget		37 (36)
Discussion about generalizability		42 (40)
Identification of limitations		81 (78)
Comparison with other studies		72 (69)

^a Value in parenthesis indicate percentage unless specified otherwise

^b As represented by clinical guidelines

indicator, application of modelling for assessing cost effectiveness, use of secondary cost and effectiveness data, adoption of a provider or payer perspective, international funding, and evaluation of preventive care—a statistically insignificant difference was noted.

3.3 Quality of Studies in India

There was a high level of agreement between the two assessors, with the kappa statistic of 87.7 %. An assessment of quality of the studies in India is presented in Table 2. The studies from India were of good quality in terms of specifying the counterfactual or comparator scenario (89 %), description of alternative scenarios (94 %), indicating sources for effectiveness data (95 %), and description of the primary outcome (93 %). However, the studies had some major limitations. The choice of the type of economic evaluation used was not well justified in a large majority of 82 % studies. There was no explanation of the perspective used in 39 % of studies. Quantity of resources were not reported separately from their unit costs in 51 % studies, while details on price adjustments for inflation or currency conversion was not reported in 35.6 % of the studies. The discounting was either not done (30 %) or lacking in justification (37 %). In about one-fifth of the studies, the conclusions were not accompanied by

appropriate caveats (19 %), or incremental analysis was not reported (21 %).


A total of 63 studies used decision analytic methods to model costs and effects. These model-based evaluations were of good quality in terms of presenting the rationale for model structure (94 %), appropriateness of model (94 %) and its time horizon (81 %), biological plausibility of the model and its disease transition states (92 %) and the choice of assumptions for transition probabilities (86 %) as reported in Table 3. The major limitation of the model-based studies in India emanate from their ability to address uncertainties involved in modelling. Only about one-third of the studies involving modelling addressed the structural uncertainties (33 %), or ran sub-group analyses to account for heterogeneity (36.5 %) or analysed methodological uncertainty (32 %).

3.4 Factors Influencing Quality of Studies

The overall quality score of economic evaluation studies in India was 65.1 % (Table 4). There was no statistically significant change in quality of studies undertaken before (61.3 %) or after (66.3 %) the year 2005. However, the quality of studies was significantly higher with the following characteristics: involvement of a foreign author as lead author (71 %) or any co-author (69.4 %); published in international journals (69.4 %); using a cost-utility design (74.1 %); and funded by an international agency (73.8 %). The quality was significantly lower for those studies where: a clinician was the lead author (60.2 %); involved evaluation of curative (57.8 %) or tertiary care (57.2 %); evaluated drugs, i.e. pharmacoeconomic studies (56 %); and those which used a patient perspective alone (55.3 %). Also, studies based on observational trials had a higher mean quality score, i.e. of 58.7 %, followed by 56.5 % among randomised trials and 51.8 % in non-randomised trials. Among model-based studies, economic evaluations based on Markov model had a higher mean quality score, i.e. of 75.5 % followed by a score of 69.9 % in decision-tree model based studies.

3.5 Cost Effectiveness of Health-Care Programmes and Interventions in India

Among HIV/AIDS-related studies, all the interventions were reported as highly cost effective (Table S1). Similarly, ICERs for immunisation and tuberculosis interventions were rated as highly cost effective. Some of the non-communicable disease interventions were reported to be highly cost effective, i.e. ECG for acute coronary syndrome, screening and delivery of hearing aids at secondary and tertiary level, school-based eye screening programme and universal gestational diabetes screening. Tele-



(* shows statistically significant at a value of < 0.05)

Fig. 2 Comparison of economic evaluation studies pre and post 2005 based on certain general and methodological characteristics. Asterisk shows statistically significant at a value of < 0.05

ophthalmology for diabetic retinopathy, school-based smoking prevention programme and primary eye care screening programme were cost-effective interventions. Among life-style interventions, only food labelling was cost effective. Use of auto-disable syringes, vitamin A supplementation, genetically modified (GM) fortification for vitamin A and treatment strategies for *Helicobacter pylori* were labelled as highly cost effective. Table S1 (supplementary material) contains the characteristics of these cost-utility studies.

Out of a total of 104 studies, 77 (74 %) authors reported the intervention as cost effective. While only 11 (10.5 %) found that intervention was not cost effective. The results of the remaining 16 (15.5 %) studies were either unclear or no strong conclusions were made by the authors.

4 Discussion

To our knowledge this paper is the first comprehensive systematic review of the evidence on economic evaluation for health care in India. Our review yielded a total of 104 full economic evaluations published from 1980 to 2014. The majority of these papers were cost-effectiveness studies (64 %), led by a clinician or public-health

professional (77 %), using decision analysis-based methods (59 %) and published in an international journal (80 %). In addition, 42 % were funded by an international funding agency or UN/ bilateral aid agency, and 30 % focussed on pharmaceuticals. The average quality score of these full economic evaluations was 65.1 %.

4.1 Extent of Economic Evaluations for Health Care in India

The absolute number of studies uncovered in the review indicates that economic evaluation in health in India is at an early stage of development. The 104 papers included in this review compares to 1249 papers on cost effectiveness published in the USA between 1979 and 1990, and 1167 published between 1991 and 1996 [123]. Nevertheless, this exceeds the number of economic evaluation studies we found when using the same inclusion criteria in relation to other developing countries such as South Africa ($n = 45$), Thailand ($n = 39$), Vietnam ($n = 26$), Bangladesh ($n = 12$), Nigeria ($n = 44$) and Zimbabwe ($n = 26$) [124–129]. However, the gap in current economic evidence in India is exacerbated by the need for region- or state-specific studies that account for variations in epidemiological transition, health-care costs, and health-care infrastructure across the country.

Table 2 Quality of economic evaluations studies for health-care interventions and programmes in India

S. no.	Quality parameter	Yes (%)	No (%)	Not applicable (%)
1	The research question is stated	104 (100)		
2	The economic importance of the research question is stated	74 (71)	30 (29)	
3	The viewpoint(s) of the analysis are clearly stated and justified	63 (61)	41 (39)	
4	The rationale for choosing the alternative programmes or interventions compared is stated	93 (89)	11 (11)	
5	The alternatives being compared are clearly described	98 (94)	6 (6)	
6	The form of economic evaluation used is stated	87 (84)	17 (16)	
7	The choice of form of economic evaluation is justified in relation to the questions addressed	19 (18)	85 (82)	
8	The source(s) of effectiveness estimates used are stated	99 (95)	5 (5)	
9	Details of the design and results of effectiveness study are given (if based on a single study)	47 (45)	9 (8)	48 (47)
10	Details of the method of synthesis or meta-analysis of estimates are given (if based on a overview of a number of effectiveness studies)	45 (43)	6 (6)	53 (51)
11	The primary outcome measure(s) for the economic evaluation are clearly stated	97 (93)	7 (7)	
12	Methods to value health states and other benefits are stated	32 (31)	13 (13)	59 (56)
13	Details of the subjects from whom valuations were obtained are given	24 (23)	18 (17.3)	62 (59.6)
14	Productivity changes (if included) are reported separately	17 (16.3)	14 (13.5)	73 (70.2)
15	The relevance of productivity changes to the study question is discussed	24 (23)	13 (13)	67 (64)
16	Quantities of resources are reported separately from their unit costs	51 (49)	53 (51)	
17	Methods for the estimation of quantities and unit costs are described	75 (72)	29 (28)	
18	Currency and price data are recorded	71 (68)	33 (32)	
19	Details of currency of price adjustments for inflation or currency conversion are given	67 (64.4)	37 (35.6)	
20	Details of any model used are given	61 (59)	2 (2)	41 (39)
21	The choice of model used and the key parameters on which it is based are justified	59 (57)	5 (5)	40 (38)
22	Time horizon of costs and benefits is stated	87 (84)	17 (16)	
23	The discount rate(s) is stated	63 (60)	31 (30)	10 (10)
24	The choice of rate(s) is justified	31 (30)	32 (31)	41 (39)
25	An explanation is given if costs or benefits are not discounted ^a	5 (5)	38 (37)	60 (58)
26	Details of statistical tests and confidence intervals are given for stochastic data	40 (38)	7 (7)	57 (55)
27	The approach to sensitivity analysis is given	70 (67.3)	18 (17.3)	16 (15.4)
28	The choice of variables for sensitivity analysis is justified	60 (57.7)	14 (13.5)	30 (29)
29	The ranges over which the variables are varied are stated	66 (63.5)	11 (10.5)	27 (26)
30	Relevant alternatives are compared	100 (96)	4 (4)	
31	Incremental analysis is reported	82 (79)	22 (21)	
32	Major outcomes are presented in a disaggregated as well as aggregated form	84 (81)	20 (19)	
33	The answer to the study question is given	97 (93)	7 (7)	
34	Conclusions follow from the data reported	97 (93)	7 (7)	
35	Conclusions are accompanied by the appropriate caveats	84 (81)	20 (19)	

^a In one of the study the explanation was not clear regarding the discounting of costs or benefits

A number of factors could explain this relative lack of economic evidence for health-care interventions and programmes. Firstly, the specialty of health economics is nascent in India. Two associations for health economics—the Indian Health Economics and Policy Association (IHEPA) and the Health Economics Association of India (HEAI) have had their inception within the last 5 years

[130, 131]. There are no specialty courses in the field of health economics for those who undertake mainstream economics courses. For example, the premier post-graduate economics department in the country—the Delhi School of Economics—does not offer a graduate course on health economics. As a result, not many mainstream economists work in the field of health. Among those in the medical and

Table 3 Quality of decision-model based economic evaluation studies for health-care interventions and programmes in India

S. no.	Quality parameter	Yes (%)	No (%)	Not clear (%)	Not applicable (%)
1	Is the rationale for model structure justified?	59 (94)	4 (6)		
2	Is the chosen model type appropriate given the decision problem and specified causal relationships within the model?	59 (94)	3 (5)	1 (1)	
3	Is the time horizon of the model sufficient to reflect all important differences between options?	51 (81)	3 (5)	9 (14)	
4	Are the time horizon of the model, the duration of treatment and the duration of treatment effect described and justified?	49 (78)	13 (21)	1 (1)	
5	Do the disease states (state transition model) or the pathways (decision tree model) reflect the underlying biological process of the disease in question and the impact of interventions?	58 (92)	2 (3)	2 (3)	1 (2)
6	Are the data identification methods transparent and appropriate given the objectives of the model?	52 (82)	11 (18)		
7	Where choices have been made between data sources, are these justified appropriately?	49 (78)	14 (22)		
8	Has the quality of the data been assessed appropriately?	50 (79)	11 (17)	2 (4)	
9	Are transition probabilities calculated appropriately?	54 (86)	3 (5)	6 (9)	
10	Have the methods and assumptions used to extrapolate short-term results to final outcomes been documented and justified?	45 (71)	16 (26)	2 (3)	
11	Have assumptions regarding the continuing effect of treatment once treatment is complete been documented and justified?	44 (70)	15 (24)	1 (2)	3 (5)
12	Have alternative assumptions regarding extrapolation or the continuing effect of treatment been explored through sensitivity analysis?	44 (70)	13 (20)	3 (5)	3 (5)
13	Have methodological uncertainties been addressed by running alternative versions of the model with different methodological assumptions?	20 (32)	43 (68)		
14	Have structural uncertainties been addressed?	21 (33)	42 (67)		
15	Has heterogeneity been dealt with by running the model separately for different subgroups?	23 (36.5)	40 (63.5)		
16	If data are incorporated as point estimates, are the ranges used for sensitivity analysis stated clearly and justified?	54 (86)	9 (14)		
17	Have the results of the model been compared with those of previous models and any differences in results explained?	38 (60)	25 (40)		

public-health stream, there have been no courses which sensitise the students on economic or more specifically—health-economics issues. Hence, there is a general lack of awareness in terms of its value or potential application in clinical or public-health research. More recently, with the creation of Schools of Public Health, a multi-disciplinary approach has been engrained in courses such as Masters of Public Health (MPH) which includes teaching on health economics. However, the limited teaching of health economics in the MPH curriculum can only be useful to generate interest and a sense of awareness for economic issues, but does not train health economists who can independently carry out full economic evaluations. More recently, a free online course on health economics has been started [132]. While these are good for introductory level, there is a limitation to which these courses can engrain the more substantive areas of micro- and macroeconomics seen

through the prism of health concerns. This may explain, to a certain extent, why economic tools and analysis remain a non-integral part of social science research in the health sector.

At the same time, adapting evaluation techniques does not necessarily require an economics degree and can be easily picked up by competent scientists and researchers who are not economists. This may explain why most studies in India are led by non-economists. A wider perspective of the health sector and a deeper understanding of core economic issues would be ideal for economic evaluation studies. This is evidenced by the finding that quality of economic evaluations was significantly high when it was conducted by an economist in the lead position, or when there was association of an author from a foreign university. The former indicates the need to bring trained economists into health sector analysis, and the latter indicates

Table 4 Factors affecting quality of economic evaluation studies for health-care interventions and programs in India

Factor	Category	Composite quality score in % (SD)	<i>p</i> value
Year of publication	Pre 2005	61.3 (15)	0.156
	Post 2005	66.3 (15.3)	
Lead author affiliation	Indian organisation	56.1 (15.5)	<0.001
	Foreign	71 (12.2)	
Involvement of any foreign author	Yes	69.4 (13.1)	<0.001
	No	54.9 (15.5)	
Lead author speciality	Clinical	60.2 (14.5)	0.006
	Economist	73.3 (7.2)	
	Public health/research	69.6 (15)	
	Member of international/UN agency	67.2 (14.6)	
	Others	53.5 (17.6)	
Publishing Journal	National	51 (16.3)	<0.001
	International	68.7 (13)	
Focus of evaluation	National	63.9 (16)	0.08
	International	71.1 (10.6)	
Type of economic evaluation	CEA	61.2 (14.6)	<0.001
	CBA	62.6 (14.1)	
	CUA	74.1 (13.6)	
Funding agency	State/National Government	63.5 (19.2)	<0.001
	UN/bilateral aid agency	70.2 (8)	
	International donors	73.8 (10.3)	
	Private agency	60.5 (13.2)	
	Not mentioned	58.8 (15.7)	
	Nil	50.9 (19.6)	
	Multiple funding agency	70.2 (8.3)	
Type of care	Preventive	68.8 (14.4)	0.001
	Curative	57.8 (14.8)	
	Both	75.4 (8.3)	
Nature of intervention	Diagnostics	67.7 (12.7)	<0.001
	Pharmaceuticals	56 (15.5)	
	Vaccine	74.4 (14)	
	Health technology	48 (21.2)	
	Service delivery	61.5 (13)	
	Public-health programme	69.8 (10)	
	Screening	68.3 (13.7)	
	Level of care of provision	Primary	
Secondary	65.7 (14.4)		
Tertiary	57.2 (16.1)		
Study design	Trial based	55.5 (13.8)	<0.001
	Modelling	71.6 (13)	
	Both	64.7 (14.2)	
Perspective	Patient	55.3 (3.8)	<0.001
	Provider/payer	64.2 (12.8)	
	Societal	73.7 (11.5)	
	Not clear	40.6 (11)	

Table 4 continued

Factor	Category	Composite quality score in % (SD)	<i>p</i> value
Alternatives	Do nothing	68.8 (14)	0.018
	Routine programme/care	64.8 (12.6)	
	Best possible	42 (8.7)	
	Other scenarios	62.1 (20.2)	
Source of cost data	Primary	58.5 (13.5)	<0.001
	Secondary	70.2 (14.7)	
	Both	72.6 (14)	
Source of effectiveness data	Primary	58.7 (13.9)	0.001
	Secondary	70 (14.5)	
	Both	62.8 (19.6)	
Type of disease	Communicable	66.1 (15.6)	0.560
	Non communicable	64.7 (14.7)	
	Others	60 (16.7)	
Overall		65.1 (15.3)	

that qualified and technically sound researchers in India are not sufficiently interested in economic evaluation studies. Only a few and not all health economists in India may be interested in economic evaluation research. The reason could be the low use of evidence-based policy making in the country. Ultimately, economic evaluation studies are publishable, but not necessarily in high demand from domestic policy makers. The incorporation of cost-effective interventions into policies in India has not necessarily been based on results from cost-effectiveness studies carried out domestically: these have mostly been driven by international evidence and best practices that are subsequently adopted in the country. This may explain the disinterest among Indian researchers to devote time to economic evaluation studies.

Despite introduction of decentralised planning process with the onset of National Rural Health Mission (NRHM), a review of the programme implementation plans (PIP) of various state governments shows no consideration of economic evidence in guiding the choice of interventions included in the plan document [133–136]. In order to improve the access to medicines, Government of India has drafted an essential list of medicines. A total of 348 drugs have been included in National List of Essential Medicines (NLEM) in India [137]. Taking a cue from the Central Government, several state governments have also drafted their own essential drug lists [138, 139]. Although the draft document on the formulation of NLEM refers to the use of criteria of cost effectiveness in determining the selection of a given drug, of the 87 experts who participated in the discussion for formulation of NLEM, none were health economists or subject experts in economic evaluations. To get more economists interested in health economics

generally and evaluation studies specifically demand must be generated either through the policy window (generating demand for such studies) or through the academic window (health economics as a field subject).

Another important factor to consider is the lack of government funding for economic evaluation studies in India, which emanates from the lack of interest among policy makers for such research. Only 6 % of the total studies were funded by the national or state government. Almost 30 % of the economic evaluation research in India was funded by international agencies or the UN/bilateral aid agencies. This explains the relatively large number of studies within the communicable disease section, which were done to evaluate HIV-related interventions. This may not be commensurate with the disease burden in India, where HIV does not figure among the top 10 causes of mortality [140]. With lack of domestic funding forthcoming, it is not surprising that there is a preponderance of non-domestic funding as well as partners in such research. Also, large programme evaluations are costly to carry out, and given the tight research funding situation in the country combined with the lack of interest in the government in evaluating existing programmes, the results of this research are not surprising. Conversely, the lack of government funding suggests that more could be done to promote the use of such evidence in policy making.

Another potential audience which could commission and use economic evaluations in health care could be various non-governmental organisations (NGO) involved in delivering health-care services such as related HIV, maternal health, child health, etc. These NGOs may not be as interested in influencing national public policy or academic debate, but may want to generate evidence to recruit

support from international funding agencies to support their expansion.

4.2 Recent Policy Developments in India

There have been recent efforts on the part of Indian government in creating political infrastructure, guidelines and policy initiatives to incorporate economic evaluations in the Indian public health sector. Firstly, a memorandum of understanding (MoU) has been signed between the Department of Health Research of India and UK National Institute of Health and Care Excellence. It would create an opportunity for the exchange of institutional expertise and experience on clinical practice guideline pathways and quality standards, application of health-technology assessment, and implementation of the decisions of the assessment into clinical policy and practice [141]. As part of this collaboration, a manual for determining the standard treatment guidelines is being developed, which also includes a chapter on the “reference case” for economic evaluations in India. Further, the Department of Health Research in India has recently set up a Medical Technology Assessment Board (MTAB) for evaluation of appropriateness and cost effectiveness of the available and new health technologies in India. At present, there is no specific and structured role of economic evaluation in the pricing and reimbursement process in Indian context, which is reflected in pricing and reimbursement system for various publicly financed health-insurance schemes, as well as drugs and diagnostics. Under various public-health insurance schemes from India such as Rashtriya Swasthya Bima Yojana (RSBY), Rajiv Aarogyasri Health Insurance Scheme or Rajiv Gandhi Jeevandayee Arogya Yojana, the reimbursement rates are based on expert opinions and not on any formal costing or cost-effectiveness analysis. Drug price control order (DPCO) 2013, which has been given the responsibility of regulating the prices of drugs under essential medicine list, also does not take into consideration any formal costing or cost-effectiveness studies. The Government of India has recently set up a separate expert group on costing, in order to guide on evidence-based reimbursement for various benefit packages under the largest publicly financed health insurance scheme in India—Rashtriya Swasthya Bima Yojana (RSBY).

The Disease Control Priorities Project 3rd edition (DCP3), which contains an up-to-date comprehensive review of the cost effectiveness of priority health interventions with the special focus on low- and middle-income countries, includes contributions from a significant number of Indian researchers. Also, some of the economic evaluations being included under this project are based purely on Indian perspective [142–144]. Thus, DCP3 has also stimulated further interest among researchers doing economic

evaluation of health interventions in India, as well as advocacy for use of such evidence by policy makers.

While it is too soon to comment on the influence of some of new initiatives mentioned earlier, on the general trend in evidenced-based policy making, indirect evidence indicates that some of the expert groups set up do not have the requisite structures to carry out evaluation studies; there seems to be a gap between intention and mechanisms required by way of resources and time—to carry out such studies. This again confirms that while global influences have prompted the government to at least acknowledge the usefulness of economic evaluation, systems are yet to be set in place to generate the kind of data required for such studies, which would necessitate a re-think on funding for such research.

4.3 Quality of Economic Evaluation Studies in India

In terms of the characteristics of the studies in India, our findings are quite similar to what has been found by others from developing country settings. Cost-effectiveness design is most predominant among the full economic evaluations undertaken in India, which is very similar to what has been reported from South Africa, Vietnam and Thailand [124–126]. Many factors could possibly explain the relative dearth of cost-utility studies. First is the application of more complex analytical methods to compute such measures. Second, there is the lack of locally available evidence on disability or quality-of-life weights. The majority (84.5 %) of the cost-utility studies used evidence on utility weights borrowed from non-Indian settings.

A major factor, which is likely to influence application of this evidence, is visibility of research to policy makers. Our review shows that a large majority of Indian research on economic evaluation is published in international (80 %), rather than national journals. This is much more than what has been reported elsewhere. This could be influenced by several factors such as higher impact factors of these international journals, their more specialised nature, i.e. covering health and economics aspects, and wider international readership. Given the preceding discussion on the results, it stands to reason to assume that publication is going to remain an important positive incentive for researchers to undertake such studies in India and those interested in high-quality publishable research would, therefore, look for outside funding, collaboration as well as best international journals to disseminate their work. This may or may not be accompanied by high visibility domestic dissemination of the results, if, in fact, there is not much interest within the country for such research. This further deepens the disconnection between policy and academic research, with low visibility of the usefulness of

evaluation studies from the perspective of policy makers, who, clearly do not have the time or interest in the academic press.

The findings of our review highlight the role of International collaboration and researchers from outside India, who have played an important role in conducting these economic evaluations. This shows that while on one hand it is important to develop local capacity for undertaking economic evaluations, it is also useful to harness such collaborations in the short term till there is national capacity built.

In terms of quality, significant areas of improvement for economic evaluation studies have been highlighted in our review. Some areas which need significant attention of the researchers are focus of the viewpoint of the evaluations being undertaken, justification on the type of economic evaluation being used, lack of use of discount rates, weak costing methodologies and the extent to which these studies address the uncertainties in methodologies of economic evaluation, especially for model-based evaluations. Overall, our findings on quality of evidence are again very similar to what others have reported in the developing countries [125–128]. However, the overall quality in India seems better than what is reported for most of other developing countries. Still, quality needs to improve to meet standards set from high-income countries and cost-effectiveness analysis (CEA) checklists to improve the usefulness of the Indian body of evidence to decision making. Nevertheless strengthening the quality of such studies through measures such as extensive training will increase the credibility of such evidence and promote uptake.

In Indian settings, the health care is financed primarily through out-of-pocket expenditure. Out-of-pocket expenditure reflects the full cost of care when patients seek care in the private sector, and partial cost when care is sought in the subsidised public sector. This cost of care, represented by out-of-pocket expenditure is captured in economic evaluations using “patient perspective”. The provider perspective is used synonymously with “payer perspective”. Payer perspective also includes insurance reimbursement or cashless provision of care for insured persons. Hence, the provider perspective includes both instances where government acts as a provider of subsidised care or instances where insurance is used to pay for the health care.

4.4 Limitations

This review has some limitations. This study included only published literature in peer-reviewed journals and excluded grey literature such as government reports, pharmaceutical company reports, academic theses and conference

proceedings. The inclusion of only published literature might have introduced publication bias, since studies with positive results are more likely to be published than studies with negative findings [145–147]. Furthermore, as in any review study, it is difficult to rule out selection bias or disagreement between the criteria of the reviewers. To minimise this bias, we used pre-defined inclusion criteria and discussion of disagreement between the investigators throughout the review process. We would also like to acknowledge that some economic evaluation studies which did include India in their analysis could have been missed in case the disaggregated results were not presented for India. We also acknowledge that the method developed by La Torre et al. is one of the ways to assess the quality of economic evaluations [14]. However, there have been other attempts such as the use of CHEERS checklist for assessing quality [148]. Besides, others have argued to apply separate weights to individual quality parameters in the checklist. A comprehensive assessment on limitations of scales for assessing quality is beyond the scope of this systematic review, and is suggested as a potentially relevant area for research in future.

5 Conclusion

The study indicates that evaluation of programmes and interventions has been somewhat sparse in the country, and also not of a very high quality. The existing body of results has been inadequate to feed into sound policy making. There is an urgent need to generate awareness within the government of how economic evaluation can inform and benefit policy making, and at the same time build capacity of health-care professionals in understanding the economic principles of health-care delivery system. The lack of demand is the main reason for these findings, and it is our belief that once the policy makers understand and demand such studies, engagement of technical experts and quality studies would be forthcoming, even if supported by outside funding. In a parallel fashion, government will have to actively encourage economists to focus on the health sector, which would go beyond the Ministry of Health and would need dialogues with the education sector. Evaluation studies remain currently somewhere in-between the medical sciences and social sciences, with neither field owning it fully. With greater demand and interest articulated by the government, India can see many more effective economic evaluation studies, done by competent researchers from both fields. While so far economic evaluation has not been a major feature of government programmes, the recent steps taken by the government need to be watched, to see whether they change the course of evidenced-based policy making in the health sector.

- pre-school children in urban slums. *Indian Pediatr.* 2000;37(1):19–29.
24. Bachewar NP, Thawani VR, Mali SN, Gharpure KJ, Shingade VP, Dakhale GN. Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and ivermectin in patients of scabies. *Indian J Pharmacol.* 2009;41(1):9–14.
 25. Bender MA, Kumarasamy N, Mayer KH, Wang B, Walensky RP, Flanigan T, et al. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. *Clin Infect Dis.* 2010;50(3):416–25.
 26. Bhagia LJ, Sadhu HG. Cost-benefit analysis of installing dust control devices in the agate industry, Khambhat (Gujarat). *Indian J Occup Environ Med.* 2008;12(3):128–31.
 27. Bhatia MR, Fox-Rushby J, Mills A. Cost-effectiveness of malaria control interventions when malaria mortality is low: Insecticide-treated nets versus in-house residual spraying in India. *Soc Sci Med.* 2004;59(3):525–39.
 28. Bhatia SJ, Kulkarni SG. Cost-effectiveness of *Helicobacter pylori* eradication in India: to live and let live ... expensively? *Indian J Gastroenterol.* 1997;16(Suppl 1):S25–8.
 29. Brown HS, Stigler M, Perry C, Dhavan P, Arora M, Reddy KS. The cost-effectiveness of a school-based smoking prevention program in India. *Health Promot Int.* 2013;28(2):178–86.
 30. Buttorff C, Hock RS, Weiss HA, Naik S, Araya R, Kirkwood BR, et al. Economic evaluation of a task-shifting intervention for common mental disorders in India. *Bull World Health Organ.* 2012;90(11):813–21. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3506405&tool=pmcentrez&rendertype=abstract>.
 31. Cecchini M, Sassi F, Lauer JA, Lee YY, Guajardo-Barron V, Chisholm D. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. *Lancet.* 2010;376(9754):1775–84 (Elsevier Ltd).
 32. Chow J, Klein EY, Laxminarayan R. Cost-effectiveness of “golden mustard” for treating vitamin a deficiency in India. *PLoS One.* 2010;5(8):e12046.
 33. Clark AD, Griffiths UK, Abbas SS, Rao KD, Privor-Dumm L, Hajjeh R, et al. Impact and cost-effectiveness of haemophilus influenzae type b conjugate vaccination in india. *J Pediatr [Internet].* 2013;163(1):S60–72. doi:10.1016/j.jpeds.2013.03.032 (Elsevier Ltd).
 34. Cook J, Jeuland M, Whittington D, Poulos C, Clemens J, Sur D, et al. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. *Vaccine.* 2008;26(50):6305–16.
 35. Dabral M. Cost-effectiveness of supplementary immunization for measles in India. *Indian Pediatr.* 2009;46(3):957–62.
 36. Dandona L, Kumar SGP, Kumar GA, Dandona R. Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India. *BMC Health Serv Res.* 2010;10:117.
 37. Dhivya PS, Swathy G, Pal S. Pharmacoeconomics of antihypertensive drugs prescribed in a multispecialty hospital in South India. *Asian J Pharm.* 2014;8(3):178–82.
 38. Diaz M, Kim JJ, Albero G, de Sanjosé S, Clifford G, Bosch FX, et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. *Br J Cancer.* 2008;99(2):230–8.
 39. Donaldson EA, Waters HR, Arora M, Varghese B, Dave P, Modi B. A cost-effectiveness analysis of India’s 2008 prohibition of smoking in public places in Gujarat. *Int J Environ Res Public Health.* 2011;8(5):1271–86.
 40. Dowdy DW, Steingart KR, Pai M. Serological testing versus other strategies for diagnosis of active tuberculosis in india: a cost-effectiveness analysis. *PLoS Med.* 2011;8(8):e1001074.
 41. Dranitsaris G, Truter I, Lubbe MS, Sriramanakoppa NN, Mendonca VM, Mahagaonkar SB. Improving patient access to cancer drugs in India: Using economic modeling to estimate a more affordable drug cost based on measures of societal value. *Int J Technol Assess Health Care.* 2011;27(1):23–30.
 42. Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, et al. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: A combined analysis of 12 mathematical models. *Lancet Glob Heal.* 2014;2(1):e23–34.
 43. Esposito DH, Tate JE, Kang G, Parashar UD. Projected impact and cost-effectiveness of a rotavirus vaccination program in India, 2008. *Clin Infect Dis.* 2011;52(2):171–7.
 44. Ferroussier O, Kumar MKA, Dewan PK, Nair PKJ, Sahu S, Wares DF, et al. Cost and cost-effectiveness of a public-private mix project in Kannur District Kerala, India, 2001–2002. *Int J Tuberc Lung Dis.* 2007;11(7):755–61.
 45. Floyd K, Arora VK, Murthy KJR, Lonnroth K, Singla N, Akbar Y, et al. Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India. *Bull World Health Organ.* 2006;84(05):437–45.
 46. Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, Divi N, et al. Clinical impact and cost effectiveness of antiretroviral therapy in India: starting criteria and second line therapy. *AIDS.* 2007;21(Suppl 4):S117–28.
 47. Frick KD, Riva-Clement L, Shankar MB. Screening for refractive error and fitting with spectacles in rural and urban India: cost-effectiveness. *Ophthalmic Epidemiol.* 2009;16(6):378–87.
 48. Fung IC-H, Guinness L, Vickerman P, Watts C, Vannela G, Vadhvana J, et al. Modelling the impact and cost-effectiveness of the HIV intervention programme amongst commercial sex workers in Ahmedabad, Gujarat, India. *BMC Public Health.* 2007;7:195.
 49. Ghoshal UC, Aggarwal R, Baba CS. Recurrent duodenal ulcer haemorrhage: a pharmacoeconomic comparison of various management strategies. *Expert Opin Pharmacother.* 2003;4:1593–603.
 50. Gogtay NJ, Kadam VS, Desai S, Kamtekar KD, Dalvi SS, Kshirsagar NA. A cost-effectiveness analysis of three anti-malarial treatments for acute, uncomplicated Plasmodium falciparum malaria in Mumbai. India. *J Assoc Physicians India.* 2003;51:877–9.
 51. Goldie SJ, O’Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. *Vaccine.* 2008;26(32):4080–93.
 52. Goldie SJ, Sweet S, Carvalho N, Natchu UCM, Hu D. Alternative strategies to reduce maternal mortality in India: a cost-effectiveness analysis. *PLoS Med.* 2010;7(4):e1000264.
 53. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. *N Engl J Med.* 2005;353(20):2158–68.
 54. Goodchild M, Sahu S, Wares F, Dewan P, Shukla RS, Chauhan LS, et al. A cost-benefit analysis of scaling up tuberculosis control in India. *Int J Tuberc Lung Dis.* 2011;15(3):358–62.
 55. Guerriero C, Cairns J, Perel P, Shakur H, Roberts I. Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the crash-2 trial. *PLoS One.* 2011;6(5):e18987.
 56. Gupta M, Prinja S, Kumar R, Kaur M. Cost-effectiveness of Haemophilus influenzae type b (Hib) vaccine introduction in the universal immunization schedule in Haryana State, India. *Health Policy Plan.* 2013;28(1):51–61.
 57. Jeuland M, Cook J, Poulos C, Clemens J, Whittington D. Cost-effectiveness of new-generation oral cholera vaccines: a multi-site analysis. *Value Health.* 2009;12(6):899–908.
 58. Jothi R, Ismail AM, Senthamarai R, Pal S. A comparative study on the efficacy, safety, and cost-effectiveness of

- bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patients. *Indian J Pharmacol.* 2010;42(6):362–5.
59. Kochhar P, Suvarna V, Duttagupta S, Sarkar S. Cost-effectiveness study comparing cefoperazone-sulbactam to a three-drug combination for treating intraabdominal infections in an Indian health-care setting. *Value Health.* 2008;11(Suppl 1):S33–8.
 60. Krishnamoorthy K, Rajendran R, Sunish IP, Reuben R. Cost effectiveness of the use of vectrol control and mass drug administration, separately or in combination, against lymphatic filariasis. *Ann Trop Med Parasitol.* 2002;96:S77–90.
 61. Kumar M, Birch S, Maturana A, Gafni A. Economic evaluation of HIV screening in pregnant women attending antenatal clinics in India. *Health Policy (N Y).* 2006;77(2):233–43.
 62. Lee BY, Bacon KM, Shah M, Kitchen SB, Connor DL, Slayton RB. The economic value of a visceral leishmaniasis vaccine in Bihar State, India. *Am J Trop Med Hyg.* 2012;86(3):417–25.
 63. Lohse N, Marseille E, Kahn JG. Development of a model to assess the cost-effectiveness of gestational diabetes mellitus screening and lifestyle change for the prevention of type 2 diabetes mellitus. *Int J Gynecol Obstet [Internet].* 2011;115 Suppl:S20–5. doi:10.1016/S0020-7292(11)60007-6 (**International Federation of Gynecology and Obstetrics**).
 64. Lubell Y, Yeung S, Dondorp AM, Day NP, Nosten F, Tjitra E, et al. Cost-effectiveness of artesunate for the treatment of severe malaria. *Trop Med Int Heal.* 2009;14(3):332–7.
 65. Mahajan R, Gupta A, Gupta RS, Gupta K. Efficacy, safety and cost-effectiveness of insulin sensitizers as add-on therapy in metabolic syndrome in patients with secondary sulfonylurea failure: a comparative study. *J Pharmacol Pharmacother.* 2010;1(2):82–6.
 66. Marseille E, Lohse N, Jiwani A, Hod M, Seshiah V, Yajnik CS, et al. The cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of a new model in India and Israel. *J Matern Fetal Neonatal Med.* 2013;26(8):802–10. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23311860>.
 67. Massad E, Behrens BC, Coutinho F a B, Behrens RH. Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries. *Malar J [Internet].* 2011;10(1):130. Available from: <http://www.malariajournal.com/content/10/1/130> (**BioMed Central Ltd**).
 68. McNeil BJ, Dudley RA, Hoop B, Metz C, Thompson M, Adelstein SJ. A cost-effectiveness analysis of screening for hepatitis B surface antigen in India. *Med Decis Making.* 1981;1(4):345–59.
 69. McNeil BJ, Thompson M, Adelstein SJ. Cost effectiveness calculations for the diagnosis and treatment of tuberculous meningitis. *Eur J Nucl Med.* 1980;5(3):271–6.
 70. Meheus F, Balasegaram M, Olliaro P, Sundar S, Rijal S, Faiz MA, et al. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. *PLoS Negl Trop Dis.* 2010;4(9). doi:10.1371/journal.pntd.0000818.
 71. Miller MA, Kane M. Routine hepatitis B immunisation in India: cost-effectiveness assessment. *Indian J Pediatr.* 2000;67(4):299–300.
 72. Mukherjee K. Cost-effectiveness of childbirth strategies for prevention of mother-to-child transmission of HIV among mothers receiving nevirapine in India. *Indian J Community Med.* 2010;35(1):29–33.
 73. Okonkwo QL, Draisma G, Der Kinderen A, Brown ML, De Koning HJ. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. *J Natl Cancer Inst.* 2008;100(18):1290–300.
 74. Over M, Marseille E, Sudhakar K, Gold J, Gupta I, Indrayan A, et al. Antiretroviral therapy and HIV prevention in India: modeling costs and consequences of policy options. *Sex Transm Dis.* 2006;33(10):S145–52.
 75. Pandav C. Economic evaluation of iodine deficiency disorder control program in Sikkim: a cost effectiveness study. *Indian J Public Health.* 2012;56(1):37.
 76. Patel AB, Dhande LA, Rawat MS. Economic evaluation of zinc and copper use in treating acute diarrhea in children: a randomized controlled trial. *Cost Eff Resour Alloc.* 2003;1(1):7.
 77. Patel V, Chisholm D, Rabe-Hesketh S, Dias-Saxena F, Andrew G, Mann A. Efficacy and cost-effectiveness of drug and psychological treatments for common mental disorders in general health care in Goa, India: A randomised, controlled trial. *Lancet.* 2003;361(9351):33–9.
 78. Paul SB, Sreenivas V, Gulati MS, Madan K, Gupta AK, Mukhopadhyay S, et al. Economic evaluation of a surveillance program of hepatocellular carcinoma (HCC) in India. *Hepatol Int.* 2008;2(2):231–6.
 79. Pho MT, Swaminathan S, Kumarasamy N, Losina E, Ponnuraja C, Uhler LM, et al. The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. *PLoS One.* 2012;7(4):e36001.
 80. Poulos C, Bahl R, Whittington D, Bhan MK, Clemens JD, Acosta CJ. A cost-benefit analysis of typhoid fever immunization programs in an Indian urban slum community. *J Health Popul Nutr.* 2004;22(3):311–21.
 81. Prinja S, Bahuguna P, Rudra S, Gupta I, Kaur M, Mehendale SM, et al. Cost effectiveness of targeted HIV prevention interventions for female sex workers in India. *Sex Transm Infect.* 2011;87(4):354–61.
 82. Rachapelle S, Legood R, Alavi Y, Lindfield R, Sharma T, Kuper H, et al. The cost-utility of telemedicine to screen for diabetic retinopathy in india. *Ophthalmology [Internet].* 2013;120(3):566–73. doi:10.1016/j.ophtha.2012.09.002 (**Elsevier Inc.**).
 83. Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z. Cost-effectiveness of the interventions. *Diabetes Care.* 2007;30(10):2548–52.
 84. Reid S. Estimating the burden of disease from unsafe injections in India: a cost-benefit assessment of the auto-disable syringe in a country with low blood-borne virus prevalence. *Indian J Community Med.* 2012;37(2):89–94.
 85. Rheingans R, Anderson JD, Anderson B, Chakraborty P, Atherly D, Pindolia D. Estimated impact and cost-effectiveness of rotavirus vaccination in India: effects of geographic and economic disparities. *Vaccine [Internet].* 2014;32 Suppl 1:A140–50. doi:10.1016/j.vaccine.2014.05.073 (**Elsevier Ltd**).
 86. Rob B, Vinod JA, Monica P, Balraj A, Job A, Norman G, et al. Costs and health effects of screening and delivery of hearing aids in Tamil Nadu, India: an observational study. *BMC Public Health.* 2009;9:135.
 87. Rose J, Hawthorn RL, Watts B, Singer ME. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. *BMJ.* 2009;339:b3653.
 88. Sahni M, Jindal K, Abraham M, Aruldas K, Puliyeel JM. Hepatitis B Immunization: cost calculation in a community based study in India. *Indian J Gastroenterol.* 2004;23(1):16–8.
 89. Schulman-Marcus J, Prabhakaran D, Gaziano TA. Pre-hospital ECG for acute coronary syndrome in urban India: a cost-effectiveness analysis. *BMC Cardiovasc Disord.* 2010;10:13.
 90. Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A. A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins - Enoxaparin, nadroparin and dalteparin: the ESCAPE-END study. *Pharmacology.* 2006;78(3):136–43.

91. Singh AJ, Garner P, Floyd K. Cost-effectiveness of public-funded options for cataract surgery in Mysore, India. *Lancet*. 2000;355(9199):180–4.
92. Singh K. Economic evaluation of Japanese encephalitis vaccination programme in Uttar Pradesh, India : a cost-benefit study. *J Vector Borne Dis*. 2014;51(1):47–52.
93. Sood S, Nambiar D. Comparative cost-effectiveness of the components of a behavior change communication campaign on HIV/AIDS in North India. *J Health Commun*. 2006;11(Suppl 2):143–62.
94. Sriram S, Aiswaria V, Cijo A, Mohankumar T. Antibiotic sensitivity pattern and cost-effectiveness analysis of antibiotic therapy in an Indian tertiary care teaching hospital. *J Res Pharm Pract*. 2013;2(2):70. Available from: <http://www.jrpp.net/text.asp?2013/2/2/70/117386>.
95. Srivastava A, Srinivas G, Misra MC, Pandav CS, Seenu V, Goyal A. Cost-effectiveness analysis of laparoscopic versus minilaparotomy cholecystectomy for gallstone disease. A randomized trial. *Int J Technol Assess Health Care*. 2001;17(4):497–502.
96. Subramaniam B, Madan R, Sadhasivam S, Sennaraj B, Tamilselvan P, Rajeshwari S, et al. Dexamethasone is a cost-effective alternative to ondansetron in preventing PONV after paediatric strabismus repair. *Br J Anaesth*. 2001;86(1):84–9.
97. Subramanian S, Sankaranarayanan R, Bapat B, Somanathan T, Thomas G, Mathew B, et al. Cost-effectiveness of oral cancer screening: Results from a cluster randomized controlled trial in India. *Bull World Health Organ*. 2009;87(3):200–6.
98. Suraratdecha C, Ramana CV, Kaipilyawar S, Krishnamurthy J, Sivalenka S, Ambatipudi N, et al. Cost and effectiveness analysis of immunization service delivery support in Andhra Pradesh, India. *Bull World Health Organ*. 2008;86(3):221–8.
99. Sutherland T, Bishai DM. Cost-effectiveness of misoprostol and prenatal iron supplementation as maternal mortality interventions in home births in rural India. *Int J Gynecol Obstet* [Internet]. 2009;104(3):189–93. doi:10.1016/j.ijgo.2008.10.011 (Elsevier Ireland Ltd).
100. Sutherland T, Meyer C, Bishai DM, Geller S, Miller S. Community-based distribution of misoprostol for treatment or prevention of postpartum hemorrhage: Cost-effectiveness, mortality, and morbidity reduction analysis. *Int J Gynecol Obstet* [Internet]. 2010;108(3):289–94. doi:10.1016/j.ijgo.2009.11.007 (International Federation of Gynecology and Obstetrics).
101. Thaker S, Mehta D, Shah H, Dave J, Kikani K. A comparative study to evaluate efficacy, safety and cost-effectiveness between Whitfield's ointment + oral fluconazole versus topical 1 % butenafine in tinea infections of skin. *Indian J Pharmacol*. 2013;45(6):622. Available from: <http://www.ijp-online.com/text.asp?2013/45/6/622/121378>.
102. Thaker S, Mehta D, Shah H, Dave J, Mundhava S. A comparative randomized open label study to evaluate efficacy, safety and cost effectiveness between topical 2 % sertaconazole and topical 1 % butenafine in tinea infections of skin. *Indian J Dermatol*. 2013;58(6):451. Available from: <http://www.e-ijd.org/text.asp?2013/58/6/451/119955>.
103. Thomas K, Peter JV, Cherian AM, Guyatt G. Cost-effectiveness of inhaled β -agonists v. oral salbutamol in asthma: A randomized double-blind cross-over study. *Natl Med J India*. 1996;9(4):159–62.
104. Uhler LM, Kumarasamy N, Mayer KH, Saxena A, Losina E, Muniyandi M, et al. Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India. *PLoS One*. 2010;5(9):1–9.
105. Van't Hoog AH, Cobelens F, Vassall A, Van Kampen S, Dorman SE, Alland D, et al. Optimal triage test characteristics to improve the cost-effectiveness of the Xpert MTB/RIF assay for TB diagnosis: A decision analysis. *PLoS One*. 2013;8(12):e82786.
106. Vassall A, Pickles M, Chandrashekar S, Boily M-C, Shetty G, Guinness L, et al. Cost-effectiveness of HIV prevention for high-risk groups at scale: an economic evaluation of the Avahan programme in south India. *Lancet Glob Heal* [Internet]. 2014;2(9):e531–40. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S2214109X14702773> (Vassall et al. Open Access article distributed under the terms of CC BY-NC-ND).
107. Venkatesh KK, Becker JE, Kumarasamy N, Nakamura YM, Mayer KH, Losina E, et al. Clinical Impact and Cost-Effectiveness of Expanded Voluntary HIV Testing in India. *PLoS One*. 2013;8(5):e64604.
108. Verguet S, Murphy S, Anderson B, Johansson KA, Glass R, Rheingans R. Public finance of rotavirus vaccination in India and Ethiopia: An extended cost-effectiveness analysis. *Vaccine* [Internet]. 2013;31(42):4902–10. doi:10.1016/j.vaccine.2013.07.014 (Elsevier Ltd).
109. Vijendra R, Kumar A, Girish K, Harsha R, Reddy V, Lakshmi P. Cost-effectiveness analysis of baclofen and chlorthalidoxepoxide in uncomplicated alcohol-withdrawal syndrome. *Indian J Pharmacol*. 2014;46(4):372. Available from: <http://www.ijp-online.com/article.asp?issn=0253-7613;year=2014;volume=46;issue=4;page=372;epage=377;aulast=Reddy>.
110. Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. *N Engl J Med*. 2013;369:1715–25. <http://www.nejm.org/doi/full/10.1056/NEJMSa1214720>.
111. Ghoshal UC, Aggarwal R, Kumar S, Naik SR. Pneumatic dilation versus intrasphincteric botulinum toxin injection in the treatment of achalasia cardia in India: an economic analysis. *Indian J Gastroenterol*. 2002;21(5):193–6.
112. Prakash C. Crucial factors that influence cost effectiveness of Universal Hepatitis B immunization in India. *Int J Technol Assess Health Care*. 2003;19(1):28–40.
113. Pantoja A, Lönnroth K, Lal SS, Chauhan LS. Economic evaluation of public-private mix for tuberculosis care and control, India. Part II. Cost and cost-effectiveness. *Int J Tuberc Lung Dis*. 2009;13(6):705–12.
114. Bindoria SV, Devkar R, Gupta I, Ranebennur V, Saggurti N, Ramesh S, et al. Development and pilot testing of HIV screening program integration within public/primary health centers providing antenatal care services in Maharashtra, India. *BMC Res Notes*. 2014;7(1):177.
115. Burke MJ, Shenton RC, Taylor MJ. The economics of screening infants at risk of hearing impairment: an international analysis. *Int J Pediatr Otorhinolaryngol*. 2012;76(2):212–8.
116. Singh SP, Hirve S, Huda MM, Banjara MR, Kumar N, Mondal D. Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs. *PLoS Negl Trop Dis*. 2011;5(2):e960.
117. Pandav CS. Economic evaluation of iodine deficiency disorder control program in Sikkim: a cost effectiveness study. *Indian J Public Heal*. 2012;56(1):37–43.
118. Vassall A, Chandrashekar S, Pickles M, Beattie T, Shetty G, Bhattacharjee P, et al. Community mobilisation and empowerment interventions as part of HIV prevention for female sex workers in Southern India: A cost-effectiveness analysis. 2014;9(10):e110562.
119. Suraratdecha C, Jacobson J, Sivalenka S, Narahari D. A cost-effectiveness analysis of strategies for controlling Japanese

- encephalitis in Andhra Pradesh, India. *J Pharm Financ Econ Policy*. 2006;15(1):21–40.
120. Olliaro P, Darley S, Laxminarayan R, Sundar S. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India. *Trop Med Int Heal*. 2009;14(8):918–25.
 121. Legood R, Gray AM, Mahé C, Wolstenholme J, Jayant K, Nene BM, et al. Screening for cervical cancer in India: How much will it cost? A trial based analysis of the cost per case detected. *Int J Cancer*. 2005;117(6):981–7.
 122. Isaac MK, Kapur R. A cost-effectiveness analysis of three different methods of psychiatric case finding in the general population. *Br J Psychiatry*. 1980;137(6):540–6.
 123. Elixhauser A, Halpern M, Schmier J, Luce BR. Health care CBA and CEA from 1991 to 1996: an updated bibliography. *Med Care*. 1998;36(5 Suppl):MS1–9 (**MS18–147**).
 124. Gavaza P, Rascati K, Oladapo AO, Khoza S. The State of Health Economic Research in South Africa: a systematic review. *Pharmacoeconomics*. 2012;30(10):925–40.
 125. Teerawattananon Y, Russell S, Mugford M. A systematic review of economic evaluation literature in Thailand: are the data good enough to be used by policy-makers? *Pharmacoeconomics*. 2007;25(6):467–79.
 126. Tran BX, Nong VM, Maher RM, Nguyen PK, Luu HN. A systematic review of scope and quality of Health Economic Evaluation Studies in Vietnam. *PLoS One*. 2014;9(8):e103825. Available from: <http://dx.plos.org/10.1371/journal.pone.0103825>.
 127. Hoque ME, Khan JAM, Hossain SSA, Gazi R, Rashid H, Koehlmoos TP, et al. A systematic review of economic evaluations of health and health-related interventions in Bangladesh. *Cost Eff Resour Alloc*. 2011;9:12. Available from: <http://www.resource-allocation.com/content/9/1/12> (**BioMed Central Ltd**).
 128. Gavaza P, Rascati KL, Oladapo AO, Khoza S. The state of health economic evaluation research in Nigeria: a systematic review. *Pharmacoeconomics*. 2010;28(7):539–53.
 129. Gavaza P, Rascati K, Brown C, Lawson K, Mann T. The state of health economic and pharmacoeconomic evaluation research in Zimbabwe: a review. *Curr Ther Res Clin Exp*. 2008;69(3):268–85.
 130. Indian Health Economics and Policy Association (IHEPA) [Internet]. Available from: <http://ihepa.in/>. Cited 11 Mar 2015.
 131. Health Economics Association of India (HEAI) [Internet]. Available from: <http://www.heai.org.in/>. Cited 11 Mar 2015.
 132. Online Certificate Course in Basic Health Economics [Internet]. Available from: www.healtheconomics.pgisph.in. Cited 14 Mar 2015.
 133. Ministry of Health and Family Welfare Government of India, National Rural Health Mission, Approval of State Programme Implementation Plan of NRHM 2014–15: Punjab [Internet]. Available from: http://www.pbnrhm.org/docs/pip_admin_approval_14_15.pdf. Cited 25 Aug 2015.
 134. Ministry of Health and Family Welfare Government of India, National Rural Health Mission, Approval of State Programme Implementation Plan of NRHM 2014–15: Andhra Pradesh [Internet]. Available from: <http://cfw.ap.nic.in/pdf/Final%20ROP%20Andhra%20Pradesh%202014-15.pdf>. Cited 25 Aug 2015.
 135. Ministry of Health and Family Welfare Government of India, National Rural Health Mission, Approval of State Programme Implementation Plan of NRHM 2012–13: Haryana [Internet]. Available from: http://pipnrhm-mohfw.nic.in/PIP2012-13_files/ROP%202012/Haryana/Approval%20of%20State%20Programme%20Implementation%20Plan-Haryana,%202012-13.pdf. Cited 25 Aug 2015.
 136. Ministry of Health and Family Welfare Government of India, National Rural Health Mission, Approval of State Programme Implementation Plan of NRHM: Himachal Pradesh, May 2012–13 [Internet]. Available from: http://pipnrhm-mohfw.nic.in/PIP2012-13_files/ROP%202012-13/Himachal%20Pradesh/Approval%20of%20State%20Programme%20Implementation%20Plan%20.pdf. Cited 25 Aug 2015.
 137. National List of Essential Medicines of India 2011 [Internet]. Available from: <http://pharmaceuticals.gov.in/nlem.pdf>. Cited 26 Aug 2015.
 138. Essential Medicine List (2013–14) [Internet]. Available from: <http://www.nrhmharyana.gov.in/files/essentialdruglist2013.pdf>. Cited 26 Aug 2015.
 139. List of Essential Drugs, 2013, Punjab [Internet]. Available from: <http://punjabhealth.co.in/downloads.aspx?ID=nh5DUDN8odM=&&Header=+g1BOWyDm98sKB5ssQYvWAv9KLvK9BIY>. Cited 26 Aug 2015.
 140. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional and national levels of age-specific mortality and 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2015;385(9963):117–71.
 141. NICE signs MoU with the Department of Health Research, Ministry of Health and family welfare, Government of India [Internet]. Available from: <http://www.nice.org.uk/proxy/?sourceurl=http://www.nice.org.uk/aboutnice/niceinternational/projects/nicesignsmougovernmentindia.jsp>. Cited 1 Jul 2015.
 142. Verguet S, Laxminarayan R, Jamison DT. Universal Public Finance of Tuberculosis treatment in India: an extended cost-effectiveness analysis. *Heal econ*. 2015;24:318–32.
 143. Verguet S, Murphy S, Anderson B, Johansson KA, Glass R, Rheingans R. Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis. *Vaccine* [Internet]. 2013;31(42):4902–10 (**Elsevier Ltd**).
 144. Megiddo I, Colson AR, Nandi A, Chatterjee S, Prinja S, Khera A, et al. Analysis of the Universal Immunization Programme and introduction of a rotavirus vaccine in India with IndiaSim. *Vaccine* [Internet]. 2014;32(S1):A151–61 (**Elsevier Ltd**).
 145. Freemantle N, Mason J. Publication bias in clinical trials and economic analyses. *Pharmacoeconomics*. 1997;12(1):10–6.
 146. Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, Greenberg D. Bias in published cost effectiveness studies: systematic review. *BMJ*. 2006;332(7543):699–703.
 147. Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, Kinoshian B, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. *N Engl J Med*. 1991;324(19):1362–5.
 148. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: an ISPOR Task Force Report. *Value Health*. 2013;16:231–50.